Microsoft Excel LibreOffice Calc

Bristol-Myers Squibb Co. (BMY)

Statement of Financial Position, Liabilities and Stockholders' Equity

Difficulty: Beginner

  • Annual Data
  • Quarterly Data

    • The statement of financial position provides creditors, investors, and analysts with information on company's resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company's assets as well as an indication of cash flows that may come from receivables and inventories.

    Liabilities represents obligations of a company arising from past events, the settlement of which is expected to result in an outflow of economic benefits from the entity.

    Bristol-Myers Squibb Co., Consolidated Statement of Financial Position, Liabilities and Stockholders' Equity

    USD $ in millions

    Microsoft Excel LibreOffice Calc
    Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014 Dec 31, 2013
    Short-term debt obligations 987  992  139  590  359 
    Accounts payable 2,248  1,664  1,565  2,487  2,559 
    Accrued rebates and returns 2,024  1,680  1,324  851  889 
    Employee compensation and benefits 869  818  904  892  735 
    Research and development 783  718  553  445  380 
    Dividends 654  660  655  645  634 
    Royalties 285  246  161  213  173 
    Branded Prescription Drug Fee 303  234  112  – –
    Restructuring 155  90  89  128  73 
    Pension and postretirement benefits 40  44  47  47  47 
    Litigation and other settlements 38  43  189  43  65 
    Other 863  738  704  691  679 
    Accrued liabilities 6,014  5,271  4,738  3,955  3,675 
    Deferred income 83  762  1,003  1,167  756 
    Income taxes payable 231  152  572  262  160 
    Liabilities related to assets held-for-sale – – – – 4,931 
    Current liabilities 9,563  8,841  8,017  8,461  12,440 
    Deferred income 454  547  586  770  769 
    Income taxes payable 3,548  973  742  560  823 
    Pension and other liabilities 1,164  1,283  1,429  1,733  1,343 
    Long-term debt, excluding current portion 6,975  5,716  6,550  7,242  7,981 
    Non-current liabilities 12,141  8,519  9,307  10,305  10,916 
    Total liabilities 21,704  17,360  17,324  18,766  23,356 
    Preferred stock, $2 convertible series, par value $1 per share – – – – –
    Common stock, par value of $0.10 per share 221  221  221  221  221 
    Capital in excess of par value of stock 1,898  1,725  1,459  1,507  1,922 
    Accumulated other comprehensive loss (2,289) (2,503) (2,468) (2,425) (2,141)
    Retained earnings 31,160  33,513  31,613  32,541  32,952 
    Cost of treasury stock (19,249) (16,779) (16,559) (16,992) (17,800)
    Total Bristol-Myers Squibb Company shareholders' equity 11,741  16,177  14,266  14,852  15,154 
    Noncontrolling interest 106  170  158  131  82 
    Total equity 11,847  16,347  14,424  14,983  15,236 
    Total liabilities and equity 33,551  33,707  31,748  33,749  38,592 
    Source: Bristol-Myers Squibb Co., Annual Reports
    Item Description The company
    Accounts payable Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Bristol-Myers Squibb Co.'s accounts payable increased from 2015 to 2016 and from 2016 to 2017.
    Current liabilities Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. Bristol-Myers Squibb Co.'s current liabilities increased from 2015 to 2016 and from 2016 to 2017.
    Non-current liabilities Total obligations incurred as part of normal operations that is expected to be repaid beyond the following twelve months or one business cycle. Bristol-Myers Squibb Co.'s non-current liabilities declined from 2015 to 2016 but then increased from 2016 to 2017 exceeding 2015 level.
    Total liabilities Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. Bristol-Myers Squibb Co.'s total liabilities increased from 2015 to 2016 and from 2016 to 2017.
    Total Bristol-Myers Squibb Company shareholders' equity Total of all Stockholders' Equity (deficit) items, net of receivables from officers, directors owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). Bristol-Myers Squibb Co.'s total Bristol-Myers Squibb Company shareholders' equity increased from 2015 to 2016 but then declined significantly from 2016 to 2017.
    Total equity Total of Stockholders' Equity (deficit) items, net of receivables from officers, directors owners, and affiliates of the entity including portions attributable to both the parent and noncontrolling interests (previously referred to as minority interest), if any. The entity including portions attributable to the parent and noncontrolling interests is sometimes referred to as the economic entity. Bristol-Myers Squibb Co.'s total equity increased from 2015 to 2016 but then declined significantly from 2016 to 2017.